2025 Q4 -tulosraportti
UUTTA
3 päivää sitten
‧25 min
1,00 NOK/osake
Irtoamispäivä 22.5.
5,87%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
198
Myynti
Määrä
249
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 132 | - | - | ||
| 5 | - | - | ||
| 113 | - | - | ||
| 1 | - | - | ||
| 530 | - | - |
Ylin
21,5VWAP
Alin
21,1VaihtoMäärä
0,1 4 110
VWAP
Ylin
21,5Alin
21,1VaihtoMäärä
0,1 4 110
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sitten7,5 % direct yield at today's price around 20 kroner is not something many can match. In addition, Vistin has significant growth potential without the need for large new investments, and very solid equity. All arrows point upwards – this could become exciting when the larger players start to position themselves. A price increase of 50 % to kr 30,- during 2026 is not unrealistic based on today's development.
·3 päivää sittenYes, no interest-bearing debt, the investments have been made and a market that (unfortunately) has certain volume growth in the foreseeable future. A risk when the volume expansion is fully completed, could be that management gets the urge to make unprofitable, new investments.
·2 päivää sittenI strongly doubt that. Just take the CF pharma investment as an example. Bought a minority stake very cheaply to look under the hood. Disciplined and cautious. Exactly what one should be when one already has a company with a high return on invested capital.- ·3 päivää sittenIncomprehensible development. The company once again delivers a strong quarter and year. This year, EPS increases to 2.7. That gives a P/E below 10 for a company with 30% return on capital. With a required rate of return of 8% and terminal growth of 2%, that gives a fair multiple of 14-15x, which implies 30kr per share.
·3 päivää sittenWhy is this stock falling on good news?- ·28.1.In Asia, the price of metformin is being dumped, is it because Vistin is gaining market share with a better quality product, or will it also push down the price for Vistin. The product is nevertheless so cheap that I think quality wins over price, we will get an indication of that soon when the Q4 figures come.·28.1.This is what AI answers about the text above: The Metformin market is rapidly changing, and Vistin is in a position that few other manufacturers can match. While Asia experiences price pressure and increasing regulatory requirements, Vistin delivers stable quality, high purity, and documented supply security. It is precisely these factors that make large pharmaceutical companies increasingly prioritize quality over the lowest price. The figures from 2025 clearly show it: Vistin increases production, grows in volume, and maintains margins even in a global price decline. That means one thing – they are gaining market share. As the company now approaches the earnings presentation for Q4 2025, it will be particularly interesting to see how they guide for 2026. With the capacity to expand production and a quality that sets the standard in the market, Vistin can become one of the winners in a market otherwise characterized by uncertainty. The question is no longer whether price pressure in Asia will drag Europe down. The more relevant question is whether Asian manufacturers can raise their quality enough to compete – and if so, whether they will have to increase prices. In the meantime, Vistin stands firm, and that is precisely why the company is so exciting right now.
- ·21.1.Less than a month until q4 figures, the company most likely delivers a dividend.
·28.1.This is among the best priced shares you find on Oslo børs, the management is skilled, and equally important, disciplined. The investments in increased production capacity have been made, so now it's about realizing the effects during the next quarters, as well as securing sales at the right price when volume increases. Metformin is the industry standard for diabetes treatment and even with Ozempic and other GLP-1 active substances, the demand for Metformin is increasing as the number of overweight (diabetes) is increasing globally. They have a decent breadth in customers (not critical if 1-3 customers are lost) Utilized capacity is significantly below potential and the cost base is relatively stable after water recycling was implemented. In addition to a fixed price for electricity which was negotiated in 2022 with Statkraft and is valid until 2032 The uncertainty lies in the price development of Premium Metformin as Vistin does not compete directly against low-cost production in China/India. This has been relatively stable from what I have seen in 2025. So there should be no surprises in Q4. Eur/nok has remained relatively stable so it will have little impact. Given decent sales efforts, the stock should probably make a small jump on the Q4 figures, but it's possible one might have to wait until Q1. At today's Metformin prices and full utilization of production capacity, we should see the stock at 29-31 by 2026. Based on the pricing of comparable companies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
3 päivää sitten
‧25 min
1,00 NOK/osake
Irtoamispäivä 22.5.
5,87%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sitten7,5 % direct yield at today's price around 20 kroner is not something many can match. In addition, Vistin has significant growth potential without the need for large new investments, and very solid equity. All arrows point upwards – this could become exciting when the larger players start to position themselves. A price increase of 50 % to kr 30,- during 2026 is not unrealistic based on today's development.·3 päivää sittenYes, no interest-bearing debt, the investments have been made and a market that (unfortunately) has certain volume growth in the foreseeable future. A risk when the volume expansion is fully completed, could be that management gets the urge to make unprofitable, new investments.·2 päivää sittenI strongly doubt that. Just take the CF pharma investment as an example. Bought a minority stake very cheaply to look under the hood. Disciplined and cautious. Exactly what one should be when one already has a company with a high return on invested capital.
- ·3 päivää sittenIncomprehensible development. The company once again delivers a strong quarter and year. This year, EPS increases to 2.7. That gives a P/E below 10 for a company with 30% return on capital. With a required rate of return of 8% and terminal growth of 2%, that gives a fair multiple of 14-15x, which implies 30kr per share.
- ·3 päivää sittenWhy is this stock falling on good news?
- ·28.1.In Asia, the price of metformin is being dumped, is it because Vistin is gaining market share with a better quality product, or will it also push down the price for Vistin. The product is nevertheless so cheap that I think quality wins over price, we will get an indication of that soon when the Q4 figures come.·28.1.This is what AI answers about the text above: The Metformin market is rapidly changing, and Vistin is in a position that few other manufacturers can match. While Asia experiences price pressure and increasing regulatory requirements, Vistin delivers stable quality, high purity, and documented supply security. It is precisely these factors that make large pharmaceutical companies increasingly prioritize quality over the lowest price. The figures from 2025 clearly show it: Vistin increases production, grows in volume, and maintains margins even in a global price decline. That means one thing – they are gaining market share. As the company now approaches the earnings presentation for Q4 2025, it will be particularly interesting to see how they guide for 2026. With the capacity to expand production and a quality that sets the standard in the market, Vistin can become one of the winners in a market otherwise characterized by uncertainty. The question is no longer whether price pressure in Asia will drag Europe down. The more relevant question is whether Asian manufacturers can raise their quality enough to compete – and if so, whether they will have to increase prices. In the meantime, Vistin stands firm, and that is precisely why the company is so exciting right now.
- ·21.1.Less than a month until q4 figures, the company most likely delivers a dividend.·28.1.This is among the best priced shares you find on Oslo børs, the management is skilled, and equally important, disciplined. The investments in increased production capacity have been made, so now it's about realizing the effects during the next quarters, as well as securing sales at the right price when volume increases. Metformin is the industry standard for diabetes treatment and even with Ozempic and other GLP-1 active substances, the demand for Metformin is increasing as the number of overweight (diabetes) is increasing globally. They have a decent breadth in customers (not critical if 1-3 customers are lost) Utilized capacity is significantly below potential and the cost base is relatively stable after water recycling was implemented. In addition to a fixed price for electricity which was negotiated in 2022 with Statkraft and is valid until 2032 The uncertainty lies in the price development of Premium Metformin as Vistin does not compete directly against low-cost production in China/India. This has been relatively stable from what I have seen in 2025. So there should be no surprises in Q4. Eur/nok has remained relatively stable so it will have little impact. Given decent sales efforts, the stock should probably make a small jump on the Q4 figures, but it's possible one might have to wait until Q1. At today's Metformin prices and full utilization of production capacity, we should see the stock at 29-31 by 2026. Based on the pricing of comparable companies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
198
Myynti
Määrä
249
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 132 | - | - | ||
| 5 | - | - | ||
| 113 | - | - | ||
| 1 | - | - | ||
| 530 | - | - |
Ylin
21,5VWAP
Alin
21,1VaihtoMäärä
0,1 4 110
VWAP
Ylin
21,5Alin
21,1VaihtoMäärä
0,1 4 110
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
UUTTA
3 päivää sitten
‧25 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
1,00 NOK/osake
Irtoamispäivä 22.5.
5,87%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sitten7,5 % direct yield at today's price around 20 kroner is not something many can match. In addition, Vistin has significant growth potential without the need for large new investments, and very solid equity. All arrows point upwards – this could become exciting when the larger players start to position themselves. A price increase of 50 % to kr 30,- during 2026 is not unrealistic based on today's development.·3 päivää sittenYes, no interest-bearing debt, the investments have been made and a market that (unfortunately) has certain volume growth in the foreseeable future. A risk when the volume expansion is fully completed, could be that management gets the urge to make unprofitable, new investments.·2 päivää sittenI strongly doubt that. Just take the CF pharma investment as an example. Bought a minority stake very cheaply to look under the hood. Disciplined and cautious. Exactly what one should be when one already has a company with a high return on invested capital.
- ·3 päivää sittenIncomprehensible development. The company once again delivers a strong quarter and year. This year, EPS increases to 2.7. That gives a P/E below 10 for a company with 30% return on capital. With a required rate of return of 8% and terminal growth of 2%, that gives a fair multiple of 14-15x, which implies 30kr per share.
- ·3 päivää sittenWhy is this stock falling on good news?
- ·28.1.In Asia, the price of metformin is being dumped, is it because Vistin is gaining market share with a better quality product, or will it also push down the price for Vistin. The product is nevertheless so cheap that I think quality wins over price, we will get an indication of that soon when the Q4 figures come.·28.1.This is what AI answers about the text above: The Metformin market is rapidly changing, and Vistin is in a position that few other manufacturers can match. While Asia experiences price pressure and increasing regulatory requirements, Vistin delivers stable quality, high purity, and documented supply security. It is precisely these factors that make large pharmaceutical companies increasingly prioritize quality over the lowest price. The figures from 2025 clearly show it: Vistin increases production, grows in volume, and maintains margins even in a global price decline. That means one thing – they are gaining market share. As the company now approaches the earnings presentation for Q4 2025, it will be particularly interesting to see how they guide for 2026. With the capacity to expand production and a quality that sets the standard in the market, Vistin can become one of the winners in a market otherwise characterized by uncertainty. The question is no longer whether price pressure in Asia will drag Europe down. The more relevant question is whether Asian manufacturers can raise their quality enough to compete – and if so, whether they will have to increase prices. In the meantime, Vistin stands firm, and that is precisely why the company is so exciting right now.
- ·21.1.Less than a month until q4 figures, the company most likely delivers a dividend.·28.1.This is among the best priced shares you find on Oslo børs, the management is skilled, and equally important, disciplined. The investments in increased production capacity have been made, so now it's about realizing the effects during the next quarters, as well as securing sales at the right price when volume increases. Metformin is the industry standard for diabetes treatment and even with Ozempic and other GLP-1 active substances, the demand for Metformin is increasing as the number of overweight (diabetes) is increasing globally. They have a decent breadth in customers (not critical if 1-3 customers are lost) Utilized capacity is significantly below potential and the cost base is relatively stable after water recycling was implemented. In addition to a fixed price for electricity which was negotiated in 2022 with Statkraft and is valid until 2032 The uncertainty lies in the price development of Premium Metformin as Vistin does not compete directly against low-cost production in China/India. This has been relatively stable from what I have seen in 2025. So there should be no surprises in Q4. Eur/nok has remained relatively stable so it will have little impact. Given decent sales efforts, the stock should probably make a small jump on the Q4 figures, but it's possible one might have to wait until Q1. At today's Metformin prices and full utilization of production capacity, we should see the stock at 29-31 by 2026. Based on the pricing of comparable companies.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
198
Myynti
Määrä
249
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 132 | - | - | ||
| 5 | - | - | ||
| 113 | - | - | ||
| 1 | - | - | ||
| 530 | - | - |
Ylin
21,5VWAP
Alin
21,1VaihtoMäärä
0,1 4 110
VWAP
Ylin
21,5Alin
21,1VaihtoMäärä
0,1 4 110
Välittäjätilasto
Dataa ei löytynyt